Eyal Ron - Polyrizon Chief Officer
| PLRZ Stock | 0.91 0.02 2.15% |
Executive
Eyal Ron is Chief Officer of Polyrizon Ltd Ordinary
| Age | 69 |
| Address | 5 Ha-Tidhar Street, Ra'anana, Israel, 4366507 |
| Phone | 972 5 5433 5665 |
| Web | https://www.polyrizon-biotech.com |
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Cathy Carew | Verastem | N/A | |
| Joakim Wijkstrom | Vanda Pharmaceuticals | 58 | |
| Kathleen MD | Verona Pharma PLC | 66 | |
| John MD | Verastem | 47 | |
| Eric Brophy | Vigil Neuroscience | N/A | |
| Colleen Mockbee | Verastem | N/A | |
| David Gray | Vigil Neuroscience | 49 | |
| Jaakko MD | VistaGen Therapeutics | N/A | |
| Kavita Aggarwal | Verona Pharma PLC | N/A | |
| Gabriela Jairala | Vincerx Pharma | N/A | |
| Cheryl Madsen | Viracta Therapeutics | N/A | |
| Karen Quarford | Vincerx Pharma | N/A | |
| Jessica PMP | Vigil Neuroscience | N/A | |
| Beatrix StelteLudwig | Vincerx Pharma | N/A | |
| MD MSc | Verastem | 67 | |
| Stewart Brown | Viracta Therapeutics | N/A | |
| Robert McRae | Viracta Therapeutics | N/A | |
| Nate Sanburn | Verastem | N/A | |
| Michael Faerm | Viracta Therapeutics | 57 | |
| Christian Mirescu | Vigil Neuroscience | N/A | |
| Caroline Diaz | Verona Pharma PLC | N/A | |
Polyrizon Ordinary Leadership Team
Elected by the shareholders, the Polyrizon's board of directors comprises two types of representatives: Polyrizon inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Polyrizon. The board's role is to monitor Polyrizon's management team and ensure that shareholders' interests are well served. Polyrizon's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Polyrizon's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nir Yosef, Chief Officer | ||
| Tomer Izraeli, CEO Founder | ||
| Tidhar Turgeman, Chief Officer | ||
| Eyal Ron, Chief Officer | ||
| Daphna Avital, Chief Officer |
Polyrizon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Polyrizon a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Total Debt | 200 K | ||||
| Total Asset | 559 K | ||||
| Retained Earnings | (3.52 M) | ||||
| Working Capital | (448 K) | ||||
| Net Asset | 559 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Polyrizon Stock Analysis
When running Polyrizon's price analysis, check to measure Polyrizon's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Polyrizon is operating at the current time. Most of Polyrizon's value examination focuses on studying past and present price action to predict the probability of Polyrizon's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Polyrizon's price. Additionally, you may evaluate how the addition of Polyrizon to your portfolios can decrease your overall portfolio volatility.